While unprofitable businesses like biotech and mining exploration companies may not see their stock prices immediately drop, they carry risks due to potential cash burn. Analyzing Acasti Pharma's cash runway and cash burn trajectory, shareholders should consider the company's ability to raise more capital in the future.